^
Association details:
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
New
Title:

Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma

Excerpt:
...a 46-year-old man who presented with a locally advanced pancreatic head mass consistent with PDAC...Additional genetic alterations included a homozygous CDKN2A deletion, TP53 splice site mutation (c.994-1G>C), SMAD4 nonsense mutation (c.247C>T, p.Q83*), and FGFR1 missense mutation (c.422C>G, p.T141R). The patient was treated with crizotinib alone, but experienced progression after 2 months, with development of leptomeningeal disease and secondary spinal cord compression.
DOI:
https://doi.org/10.6004/jnccn.2017.0058